Guggenheim raised the firm’s price target on Sophia Genetics (SOPH) to $7 from $6 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOPH:
- SOPHiA GENETICS Announces CEO Transition and Strong Preliminary 2025 Results
- SOPHiA GENETICS Posts Strong 2025 Preliminary Results and Sets CEO Transition for 2026
- Sophia Genetics sees Q4 revenue ‘at least’ $21M, consensus $20.5M
- Sophia Genetics sees FY25 revenue of about $77M, consensus $76.2M
- Sophia Genetics sees FY26 revenue $92M-$94M, consensus $88.0M